Clinical research

A prospective evaluation of the safety and efficacy of TAXUS Element paclitaxel-eluting coronary stent implantation for the treatment of de novo coronary artery lesions in small vessels: the PERSEUS Small Vessel trial

EuroIntervention 2011;6:920-927.

Louis A. Cannon
Louis A. Cannon1, MD; Dean J. Kereiakes2*, MD; Tift Mann3, MD; Jeffrey J. Popma4, MD; Michael R. Mooney5, MD; Gregory J. Mishkel6, MD; Tommy C. Lee7, MD; B. Hadley Wilson8, MD; Thomas D. Stuckey9, MD; Steven Orlow10, MD; Thomas McGarry11, MD; Michael E. Ring12, MD; Mirle A. Kellett13, MD; Paul Underwood14, MD; Keith D. Dawkins14, MD
1. Cardiac and Vascular Research Center of Northern Michigan, Northern Michigan Regional Hospital, Petoskey, MI, USA; 2. The Christ Hospital Heart and Vascular Center/The Lindner Center for Research and Education at The Christ Hospital, Cincinnati, OH, US

Aims: Small reference vessel diameter predicts adverse outcomes following coronary stenting. TAXUS Express and TAXUS Liberté paclitaxel-eluting stents (PES) reduce restenosis compared to ba

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
The outcome of bifurcation lesion stenting using a biolimuseluting stent with a bio-degradable polymer compared to a sirolimus-eluting stent with a durable polymer

Latest news